APPILI THERAPEUTICS INC-CL A (APLI.CA)
CA03783R1073 - Common Stock
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Court’s approval allows transaction with Aditxt to...
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
Overwhelming shareholder support in favour of take-private transaction with Aditxt Studies presented at IDWeek 2024™ demonstrate ATI-1701 provides full...
Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
Appili Therapeutics Announces Results of Special Meeting of Shareholders
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Nov. 06, 2024 (GLOBE NEWSWIRE)...
Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies Appili provides update on Aditxt transaction and encourages shareholders...
Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership with Broader Perspectives
Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024
ATI-1701 provides full protection against lethal tularemia in animal models after one year Company to provide update on tularemia vaccine candidate...
Appili Therapeutics – Press Release Correction
HALIFAX, Nova Scotia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), announces...
Appili Therapeutics Announces Mailing of the Management Information Circular in Connection with the Special Meeting of Shareholders
Your vote is important no matter how many votes you hold.Shareholders who have questions or need assistance with voting their shares should contact...
Aditxt Delivers Shareholder Update and 2024 Year-End Plan
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
HALIFAX, Nova Scotia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a...
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics
Appili Therapeutics Announces Third Amendment to Arrangement Agreement and Provides Updated on Transaction with Aditxt
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Aug. 21, 2024 (GLOBE NEWSWIRE)...
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2025
Definitive agreement with Aditxt, if approved by Appili shareholders, provides significant premium to shareholders and resources to advance key programs ...
Appili Therapeutics Announces Second Amendment to Arrangement Agreement
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 18, 2024 (GLOBE NEWSWIRE)...
Appili Therapeutics Announces Amendment to Arrangement Agreement and Increase to Bridge Loan
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 02, 2024 (GLOBE NEWSWIRE)...
Appili Therapeutics Reports Fiscal Year 2024 Financial and Operational Results
Appili Therapeutics Reports Fiscal Year 2024 Financial and Operational Results...
Appili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 26, 2024 (GLOBE NEWSWIRE)...
Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.
Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and...
Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks
A review of Russian and English literature suggests that Appili’s biodefense program ATI-1701 may have a role in preventing tularemia in Ukraine...
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024
FDA approved LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL Additional USAFA funding commitment from the U.S. Air Force Academy, intended...
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024
Appili Therapeutics’ Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy
Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update
Appili Therapeutics Presents at the 10th International Tularemia Conference
Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024
